Stage IV Small Lymphocytic Lymphoma (DBCOND0028635)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00489203	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	Beclomethasone dipropionate Methotrexate Tacrolimus	supportive_care	2	completed
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	Palifermin	supportive_care	Not Available	completed
NCT00089154	Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Apolizumab	treatment	2	completed
NCT00293345	3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma	Gemcitabine Triapine	treatment	1	completed
NCT00054483	Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction	Bortezomib Bortezomib D-mannitol	basic_science	1	completed
NCT00608361	Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery	Dasatinib	treatment	1	completed
NCT01045928	Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Lenalidomide Rituximab	treatment	1	terminated
NCT01129193	AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma	AR-42	treatment	1	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT01076556	Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Alvocidib Cyclophosphamide Rituximab	treatment	1	terminated
NCT00354185	PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma	Belinostat Tanespimycin	treatment	1	terminated
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT01805037	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	Brentuximab vedotin Rituximab	treatment	1 / 2	terminated
NCT00003970	Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma	Irinotecan	treatment	1	completed
NCT02213913	Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas	Cyclophosphamide Doxorubicin Etoposide Lenalidomide Prednisone Rituximab Sulfate ion Vincristine	treatment	1 / 2	active_not_recruiting
NCT00104858	Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Cyclosporine Fludarabine Mycophenolate mofetil Rituximab	treatment	2	completed
NCT01158274	RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors	Capecitabine RG-4733	treatment	1	completed
NCT00058227	Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma	Alvocidib Fludarabine Rituximab	treatment	1	completed
NCT00098891	MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas	Entinostat Isotretinoin	treatment	1	completed
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT00010192	Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer	Aldesleukin Rituximab	treatment	1	completed
NCT00101244	SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	Ispinesib	treatment	1	terminated
NCT01682044	Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma	Filgrastim Pegfilgrastim Rituximab	treatment	2	completed
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT00003204	Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma	Cyclophosphamide Fludarabine Prednisone Rituximab Sulfate ion Vincristine	treatment	3	completed
NCT00377104	Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Alvocidib	treatment	1	terminated
NCT00049504	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00891072	Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Carboplatin Isosorbide Paclitaxel	treatment	1	completed
NCT00040846	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00060112	Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma	Gemcitabine	treatment	1	terminated
NCT00017381	Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	Cyclophosphamide Filgrastim Rituximab	treatment	0	completed
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT00019708	Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	Tanespimycin	treatment	1	terminated
NCT01959477	Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant	Busulfan Cyclophosphamide Etoposide	treatment	0	completed
NCT00476047	Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission	Tositumomab	treatment	2	completed
NCT01044745	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Rituximab Tacrolimus	treatment	2	terminated
NCT00096005	Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT00089011	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00499811	Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction	Vorinostat	treatment	1	completed
NCT00112593	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT00089271	17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas	Alvespimycin	treatment	1	completed
NCT00947388	Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)	Alemtuzumab Bendamustine	treatment	1	terminated
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Fludarabine Melphalan	treatment	Not Available	completed
NCT00769288	FAU in Treating Patients With Advanced Solid Tumors or Lymphoma	No drug interventions	treatment	1	completed
NCT02037256	Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma	Bortezomib Bortezomib D-mannitol Filgrastim	treatment	Not Available	completed
NCT00348985	PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas	Belinostat Bortezomib Bortezomib D-mannitol	treatment	1	completed
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Filgrastim Plerixafor	treatment	Not Available	terminated
NCT00118170	Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	Sorafenib	treatment	1	completed
NCT00004241	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma	Tanespimycin	treatment	1	completed
NCT01273766	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies	Deferasirox	supportive_care	2	completed
NCT00275080	Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia	2'-Deoxycytidine Decitabine Vorinostat	treatment	1	completed
NCT02005289	Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL	Lenalidomide Tafasitamab	treatment	2	active_not_recruiting
NCT00288067	Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Fenretinide Rituximab	treatment	1 / 2	terminated
NCT00105001	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Sirolimus Tacrolimus	treatment	2	completed
NCT00017472	Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia	Apolizumab	treatment	1	completed
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT01024010	Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Cyclophosphamide Ofatumumab Pentostatin	treatment	2	completed
NCT01789255	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies	Cyclosporine Methotrexate Tacrolimus Vorinostat	supportive_care	2	completed
NCT00077155	Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma	Cilengitide	treatment	1	completed
NCT00918723	Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Cyclophosphamide Fludarabine Rituximab Vorinostat	treatment	1 / 2	completed